Three Digital Core Biopsies Sufficient to Determine PD-L1 Expression in NSCLC
Sep 25, 2018
Four or more biopsies proffer little additional benefit, found a study presented at the IASLC 19th World Conference on Lung Cancer.
Recent Content
How Pathology Changed the Lung Care Landscape
Sep 25, 2018
In recent years, advances in the molecular analysis of tumors and pathologic investigation have improved understanding of an ambit of lung cancer types.
Biomarker Associated With Longer Survival Uncovered in Ovarian Cancer
Sep 25, 2018
A new proteomic analysis found that CT45 is an independent prognostic factor in patients with high-grade serous ovarian cancer, and a potential target of immunotherapies.
Are Stromal Cells Mediating Response to Immunotherapy in Bladder Cancer?
Sep 25, 2018
New research suggests that immune resistance in urothelial cancer may be mediated by stromal cells, which act as a source of EMT-related gene expression.
TRK Fusions Identified in Hematologic Cancers
Sep 24, 2018
A study shows TRK gene fusions in hematologic cancers may respond to larotrectinib.
Applying Nanotechnologies for Immunotherapy
Sep 24, 2018
Nanotechnological strategies are making preclinical strides toward more effective, less toxic, immunotherapies.
Should Dyspnea in Lung Cancer Be Medicated?
Sep 24, 2018
Two presentations at the IASLC WCLC 2018 discussed the evidence on treating breathlessness with pharmacologic vs nonpharmacologic therapy.
Pembrolizumab Alone or With Chemotherapy for PD-L1–Positive NSCLC?
Sep 24, 2018
Pembrolizumab plus chemotherapy failed to improve survival compared with pembrolizumab alone in patients with non–small-cell lung cancer.
Hyperprogression in NSCLC Patients With PD-1/PD-L1 Inhibitors
Sep 21, 2018
A study shows hyperprogressive disease (HPD) occurred more commonly among patients with pretreated non-small cell lung cancer (NSCLC) receiving PD-1/PD-L1 inhibitors.
Male Sex Ups Mortality Risk in BRAF V600E Papillary Thyroid Cancer
Sep 21, 2018
The study confirmed a significant effect of male sex on PTC-specific patient survival in individuals with the most frequent oncogenic mutation.
